Evidence map›Paper›PMID 35326627›Full record

ArticleCancers2022

Chick Chorioallantoic Membrane (CAM) Assays as a Model of Patient-Derived Xenografts from Circulating Cancer Stem Cells (cCSCs) in Breast Cancer Patients.

Monika Pizon, Dorothea Schott, Ulrich Pachmann, Rainer Schobert, Marek Pizon, Marta Wozniak, Rafal Bobinski, Katharina Pachmann

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Design and PreliminaryCurrent pharmaceutical biotechnology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Monika PizonDepartment of Research and Development, Transfusion Center Bayreuth, 95448 Bayreuth, Germany.ORCID 0000-0002-6599-3731
Dorothea SchottDepartment of Research and Development, Transfusion Center Bayreuth, 95448 Bayreuth, Germany.
Ulrich PachmannDepartment of Research and Development, Transfusion Center Bayreuth, 95448 Bayreuth, Germany.
Rainer SchobertDepartment of Organic Chemistry, University of Bayreuth, 95440 Bayreuth, Germany.ORCID 0000-0002-8413-4342
Marek PizonDepartment of Cardiac Surgery, Clinic of Bayreuth, 95455 Bayreuth, Germany.
Marta WozniakDepartment of Clinical and Experimental Pathology, Wroclaw Medical University, 50-556 Wroclaw, Poland.ORCID 0000-0001-7978-6330
Rafal BobinskiDepartment of Biochemistry and Molecular Biology, University of Bielsko-Biala, 43-309 Bielsko-Biała, Poland.
Katharina PachmannDepartment of Research and Development, Transfusion Center Bayreuth, 95448 Bayreuth, Germany.
Bayreuth Medical Center · DEUniversity of Bayreuth · DEUniversity of Bielsko-Biała · PLWroclaw Medical University · PL

Funding

Astellas Pharma (United States) N/APfizer (United States) N/A
6 · The paper itself

Abstract

backgroundcCSCs are a small subset of circulating tumor cells with cancer stem cell features: resistance to cancer treatments and the capacity for generating metastases. PDX are an appreciated tool in oncology, providing biologically meaningful models of many cancer types, and potential platforms for the development of precision oncology approaches. Commonly, mouse models are used for the in vivo assessment of potential new therapeutic targets in cancers. However, animal models are costly and time consuming. An attractive alternative to such animal experiments is the chicken chorioallantoic membrane assay.

methodsIn this study, primary cultures from cCSCs were established using the sphere-forming assay. Subsequently, tumorspheres were transplanted onto the CAM membrane of fertilized chicken eggs to form secondary microtumors.

resultsWe have developed an innovative in vitro platform for cultivation of cCSCs from peripheral blood of cancer patients. The number of tumorspheres increased significantly with tumor progression and aggressiveness of primary tumor. The number of tumorspheres was positively correlated with Ki-67, Her2 status, and grade score in primary breast tumors. The grafting of tumorspheres onto the CAM was successful and positively correlated with aggressiveness and proliferation capacity of the primary tumor. These tumors pathologically closely resembled the primary tumor.

conclusionsThe number of tumorspheres cultured from peripheral blood and the success rate of establishing PDX directly reflect the aggressiveness and proliferation capacity of the primary tumor. A CAM-based PDX model using cCSC provides a fast, low-cost, easy to handle, and powerful preclinical platform for drug screening, therapy optimization, and biomarker discovery.

Indexed as

breast cancerCAM-assaycCSCsPDXtumorspheres

Identifiers

PMID35326627
PMCPMC8946779
OpenAlexW4220654258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.